Webinars

Daniel Pollyea, MD, MS, University of Colorado Health, gives a comprehensive overview of what happens when a higher risk MDS patient transitions to AML including the diagnositic criteria, treatment options and outcomes assessments. Dr. Pollyea also reviews some of the most promising treatment options that are in clinical trial and/or new to the treatment space. He also discusses the increasing success rates for older patients who go to transplant as a curative treatment for High Risk MDS and AML. Dr. Pollyea answers a number of patient-submitted questions as well. 

Shyamala Navada, MD, MSCR, Mount Sinai Hospital, New York, provides an overview of the diagnosis and treatment of aplastic anemia and an update on new treatment options that are in the clinical trial and study phase. Dr. Navada also answers patient-submitted questions.

The COVID-19 pandemic has brought many changes to how  we live our lives,. It has brought uncertainty, altered daily routines, financial pressures, and social isolation.

In this webinar, Dr. Timothy Pearman from Northwestern University Feinberg School of Medicine and Jenny Finkel from Jenny Finkel Yoga discuss self-care strategies for patients, families and caregivers which can improve emotional health and wellness and empower participants during this difficult time. Jenny and Dr. Pearman also demonstrate accessible yoga practices which you can do at home to help keeping you moving and help relieve stress. 

In this webinar, Dr. Amer Zeidan from Yale Cancer Center discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2019 meeting in Orlando, Florida.

Research findings are explained along with the potential impact of this research on understanding and treating MDS and AML.

In this webinar, Dr. Deeg addresses the pre and post transplant concerns of bone marrow failure patients and their caregivers and reviews the precautions they should be taking to protect their health, particularly during this pandemic.

Our apologies, but this webinar had some technological challenges during the presentation and the sound quality is not ideal. We will also provide a transcript of the session which should provide clarity on the responses from Dr. Deeg to the questions submitted during the Q & A portion of the webinar. 

This webinar with Gail Roboz, MD, addresses the concerns of high-risk MDS or secondary AML patients and their caregivers and reviews the precautions they should be taking to protect their health. Patients, families and caregiver questions are included at the end of the presentation. 

Dr. DeZern and Dr. Dioverti address the concerns of bone marrow failure disease patients and their caregivers and review the precautions they should be taking to protect their health.
They also answer participant questions and answers.

Dr. Hofmann and Dr. Margolis will discuss the specific concerns related to COVID-19 for pediatric bone marrow failure patients and their parents, including pre- and post-transplant issues.   

There will be an opportunity for questions and answers via the webinar platform. 

Our presenter is Carlos M. De Castro, MD, a cell therapy and hematologic malignancies specialist who sees patients at Duke Cancer Institute in Durham, NC.  Dr. De Castro is a Professor of Medicine at Duke University School of Medicine and a member of the AAMDSIF Medical Advisory Board.  

Dr. De Castro addresses the specific concerns of aplastic anemia and PNH patients related to COVID-19.  This is a pre-recorded webinar in which patients, family members and caregivers were able to submit questions to the presenter. 

Recorded 3/13/20, this webinar features two experts, Dr. Mikkael Sekeres and Dr. Isabel Schuermeyer, who discussed how patients can deal with the outbreak of COVID-19 both physically and emotionally. After their presentation, they answered questions from the live audience.

In this webinar, Cate Lockhart - Executive Director at Biologics and Biosimilars Collective Intelligence Consortium, helps patients and families understand the difference between biologic and biosimilar medications. She discusses the approval process for FDA approval and how biosimiliar medications will impact the future of treating patients.

Dr. Michael Pulsipher, MD, describes the determination for bone marrow transplant treatment in children in order to promote positive outcomes.

In this webinar, Dr. Michael Pulsipher from Children's Hospital Los Angeles will discuss pediatric bone marrow transplant and how to optimize the best outcomes for pediatric patients after transplant. Complications can arise after transplant and Dr. Pulsipher will discuss who to protect your child's health.

Costa Herbert, RN from Fred Hutchinson Cancer Research Center discusses the transplant process so patients and caregivers can travel the transplant journey with knowledge and confidence. 

This webinar is presented in partnership with Be the Match. 

Dr Catherine Lai, Medstar Georgetown University Hospital Lombardi Comprehensive Cancer Center, discusses the challenges associated with treating MDS in older adults and what treatment options are available. 

In this webinar, Dr. Daniel Weisdorf from the University of Minnesota Clinical and Translational Science Institute will discuss what is a bone marrow transplant and the risks and benefits of a transplant for CLL patients.

Dr. Gail Roboz from Weill Cornell, discusses the advances in MDS and AML research that was reported at the annual conferences of two major hematology/oncology organizations this summer – the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).

During this webinar, Dr. Phillip Scheinberg from Hospital Sao Jose, Beneficencia Portuguesa de Sao Paolo in Brazil discusses the history of Aplastic Anemia - past, current and future thinking of the disease and treatment options.

During this webinar, Dr. Michael Burke from Children's Hospital of Wisconsin, will discuss refractory/relapsed AML, how it is diagnosed, affects on treatments and what this diagnosis means for patients. Participants will have the opportunity to ask Dr. Burke their questions.